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in rat heart (predominantly beta-l-adrenoceptors) more potently
than in rat lungs [predominantly beta-2-adrenoceptors (5)]. In
contrast, beta-2 subtype-selective drugs (IC! 118,55 1 and pro
caterol) were more potent in the lungs than in the heart (2,5).
Radioactive metabolites appeared in rat plasma, but bound
radioactivity in heart and lung represented mainly parent
compound even at 60 min postinjection (6). In vivo saturation
studies indicated receptor densities of 6.0 and 21 pmole/g tissue
in rat heart and lung, respectively (7).
Thus, animal experiments indicate that S-(fluoro)carazolol
may be a useful ligand for PET evaluation of j3-adrenoceptors
in patients suffering from asthma, chronic obstructive pulmo
nary disease, cystic fibrosis, hypertension or heart failure,
conditions which are associated with altered receptor densities
or an altered coupling of the receptors to distal parts of the
transduction chain (8â€”u3).Such studies can also be performed
with another radioligand, S-[' â€˜C]-CGP12177 (u4â€”20).How
ever, the synthesis of this compound is difficult and in our
hands not sufficiently reliable for routine clinical studies.
S-i â€˜-[â€˜8F]Fluorocarazololis more easily prepared and it may
prove a useful alternative to S-[' â€˜C]-CGP12177. Here, we




Healthy volunteers were recruited according to the following
criteria: age 18â€”40 yr, prebronchodilator forced expiratory volume
in 1 sec (FEy1) >80% of predicted, nonsmoker or ex-smoker
(smoking terminated for more than 1 yr). Excluded were people
with a positive history for wheezing and tightness of the chest,
upper respiratory tract infections in a period shorter than 4 wk
before the study, presence ofpulmonary diseases including asthma,
presence of airway hyperresponsiveness, atopy (at least one posi
tive reaction to known allergens in intracutaneousskin tests), use of
beta-mimetics or theophylline, high blood pressure or heart failure,
pregnancy or suspected pregnancy.
All volunteers underwent the following screening: anamnesis,
physical examination, routine blood biochemistry to assess kidney
and liver function, electrocardiogram, skin tests for allergic reac
tions and pulmonary function tests (spirometry and determination
of airway hyper-responsiveness).Airway responsivenessto metha
choline was determined using the 2-mm tidal breathing method of
Cockroft et al. (21,22). The study was approved by the Medical
Ethics Committee of the University Hospital. Each subject gave
written, informed consent.
s-iâ€˜-r8Flfluorocarazololw sadministeredtohealthyvolunteersto
assess its potentialfornoninvasivemeasurement of regionalpulmo
nary and myocardiaibeta-adrenoceptor densities. Methods High
specific activityfluorocarazololwas intravenouslyinjected on two
separate occasxns wfthina 1-wk interval.The in@aIinjec@onwas
wfthout pretreatment, but before the second injectkxi,the volun
teers eitherinhaledsalbutamol(2 x 200 @gaerosol)orthey ingested
pindolol(3 x 5 mgduringa 12-hrinterval).Twenty-eightPETtime
frames of3l planes were acquired overa periodof6Ommaftereach
injection.BlOOdsamples were drawn and analyzedforthe presence
of fluorocarazololandradioactivemetabolites.ResultsUptakeof
fluorocarazolol in the target tissues was hardly affected by salbuta
mol but was stronglydepressed by pindolol.Pulmonaryand myo
cardial tissue-to-p@sma concentration ratios of fluorocarazobl
reached plateau values of 11.6 Â±0.6 Qungs)and 18.1 Â±1.0 (heart)
at 45-50 mm postinjection. These values were reduced to 2.0 Â±0.4
and2.0Â±0.6aftertreatmentwithpindolol.Conclusion:Thesedata
indicate that:
1. Pulmonary and myocardialuptake of radioactivityafter intra
venous administration of S-i â€˜-C8F]fluorocarazololrepresents
radioligand binding to beta-adrenoceptors.
2. Pulmonary binding occurs mainly in alveoli rather than in
airway smooth muscle under these conditions.






studying receptors noninvasively in man. Carazolol, a lipophilic,
nonsubtype-selectivebeta-adrenoceptor antagonist, can be labeled
with the positron emitters â€˜â€˜C(u,2) or â€˜8F(3). The suitability of
carazolol for PET studies of beta-adrenoceptors has been
demonstrated in mice, rats and minipigs (1â€”6).Uptake in the
target organs (heart, lungs) is substantial and it can be blocked
(1,4) and displaced (2) by propranolol. The in vivo binding is
stereoselective as the R-isomer does not accumulate in the
target organs, which is in contrast to the S-isomer (2,3). Also,
S-propranolol is much more potent than R-propranolol in
preventing tissue uptake ofS-l â€˜-[â€˜8F]fluorocarazolol(5), which
indicates that fluorocarazolol and propranolol compete for
binding to the same receptor sites.
In vivo competition studies showed that fluorocarazolol binds
to the beta-i and beta-2-subtypes.Beta-i subtype-selective
antagonists (CGP 207i2A and ICI 89,406) inhibited â€˜8Fuptake
ReCeivedJan. 22, 1996; revisionaccepted May 7. 1996.
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S-Desisopropylcarazolol (enantiomeric excess >98%) was pre
pared as reported previously (6). S-i â€˜-[â€˜8F]fluorocarazololwas
synthesizedby reacting the precursor with [â€˜8F]fiuoroacetone(3,6)
and purified by HPLC. The specific activity was 50 Â± 24
TBq/mmole (1400 Â±680 Ci/mmole) and the radiochemical purity
was >99.8%. The ligand was dissolved in 0.5 ml ethanol/pro
pylene glycol/0.9% NaCl (1/2/2 v/v/v). Before injection this
solution was filtered (0.22 pm) and 7.5 ml 0.9% NaCl was added
via the filter. The solution was sterile and apyrogenic. S-i'-
fluorocarazolol. HC1 passed the test on â€œacuteoxicityâ€•(European
Pharmacopeia; Dutch Pharmacopeia Ed. LX) at a 10,000-fold
higher dose than was administered to humans.
SWdy Pro@
At the beginning of the study, a cannula was placed in a vein of
one ofthe lower forearms.Anothercannulawas placed in the radial
artery ofthe contralateralarm, after patency ofthe ulnar artery had
been proven by the Allen-test. The arterial cannula was inserted
under local anesthesia with lidocaine. The venous cannula was
used for injection and the arterial line for blood sampling.
The volunteer was then placed in the PET camera (FWHM 6
mm). A rectilinear scan was made for proper positioning (heart and
lungs in the field ofview). Next, a transmission scan was produced,
using the internal 68Ge/@8Gasources, to correct for attenuation.
S-1'-['8F]fluorocarazolol (on average 56 MBq = 1.5 mCi) was
injected over a period of 1 mm, using a Medrad OP-iOOremote
controlledpump. Lines were carefully flushedwith saline to ensure
complete delivery of the radioligand.
Data acquisition was started at the onset ofinjection; 8 frames of
15 sec were followed by 4 frames of 30 sec, 4 frames of 1 mm, 4
frames of 2 mm, 6 frames of 4 mm and 2 frames of 10 mm. Total




FIGURE 1. PET images of a
human volunteer acquired with
S-i â€˜-r89fluorocarazolol.Transax
ial cross-sections in the time
frame 14â€”60mmpostinjectionare
dispIayed.@The upper and third
rows are from the contr@study,
and the second and bottom rows
are from the pindOiol-blOCked
study ofthesame subject.Subse
quent planes are shown fromthe
rostral Qeft@to the caudal (right)
side of the thorax.
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meanÂ±s.d. 0.0082Â±0.001526.7 Â±2.20.0073 Â±0.001416.0 Â±2.8*2
23.40.009425.713.00.005514.33
22.60.007524.515.00.004816.3Saibutamol
mean Â±s.d. 0.0084 Â±0.001025.1 Â±0.80.0052 Â±0.000415.3 Â±1.44
16.20.014515.517.40.021816.75
13.00.015010.418.50.016014.8Pindolol
mean Â±s.d. 0.0148 Â±O.0003@13.0 Â±3.6@0.0189 Â±O.0O29@15.8 Â±1.3*Sign@fly
differentfromthe correspondingvaluefor theheart.t5jgnff@+Jy





time-activity curves observed after injec
tion of S-i â€˜-rÂ°@@@ioi (data
plottedas meanÂ±s.d.).
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were drawn at 0.5-mm intervals during the initial 5 min and at
10-mm intervals from 10 to 60 mm postinjection. Radioactivity in
plasma and in a cell pellet (5 mm 3000 g) was determined in all
samples using a gamma counter that was cross-calibrated with the
PET camera. Additional samples (3 ml) drawn at 1, 2, 5, 10,20,40
and 60 min were used for metabolite analysis (see below). The
volunteer left the camera when data acquisition had ended and the
cannulas were removed.
After an interval of at least 1 wk, the volunteer returned for the
second part of the study in which the influence of a beta-2 agonist
or a beta-adrenoceptorantagoniston tissueuptakeof S-iâ€˜-
[â€˜8F]fluorocarazololwas assessed. Two different treatments were
compared:
1. Some volunteers inhaled salbutamol (VentolinR,2 X 200 @g
aerosol) 30â€”40mm prior to injection of the radioligand.
2. Other volunteers took pindolol (ViskeenR, orally, 5 mg on the
evening before the experiment, 5 mg on the morning before
the experiment and 5 mg 30â€”40mm before injection of the
radioligand).
Cannulas were placed in a vein ofeach ofthe lower forearms.
No arterial catheter was used in the second part of the study to
keep inconvenience to the volunteer to a minimum. One
cannula was used for injection and the other for blood sampling.
Tracer injection, data acquisition and sampling were performed
as on day one.
Metab@ An@
Plasma was analyzed for the presence of S-i â€˜-[â€˜8F]fluorocara
zolol and radioactive metabolites by methods published previously
(23). Untreated plasma samples were directly applied to a Chrom
spher Biomatrix (150 x 4.6 mm i.d.) column with M3 guard
column. The mobile phase was 10 mM K2HPO4:acetonitrile (90:10
v/v, pH 7.5) and the flow rate 1.5 mi.min â€˜. Twenty-four fractions
of the eluate were collected over a period of 12 min. Radioactivity
in the fractions was determined using the gamma counter. An
independent estimate of the fraction of unmetabolized ligand was
obtained by determining protein-bound radioactivity in human
plasma by ultrafiltration (MPS-l reusable micropartition system
with YMT-30 membrane, Amicon, Beverly MA). It has been
shown previously that about 73% of native S-l â€˜-[â€˜tF]fluorocara
zolol is bound to plasma proteins, but its radioactive metabolites
have negligible protein binding (23).
Data Evaluation
Regions of interest (ROIs) were drawn on both lungs, using the
transmission scan and avoiding hilar structures. A ROl for the left
TABLE2
Parameters of the â€˜SlowKinetic Phase' of Washout in Target Tissues
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Details regarding the participants and the study protocol are
presented in Table i . All volunteers (5 men, 1 woman; age
range 21â€”36yr; median age 27 yr) had normal spirometric
values: average FEV1 103% of predicted, range 92%â€”114%,
average vital capacity 105 (92â€”123)% ofpredicted. None of the
subjects showed bronchial hyperresponsiveness to methacho
line: the provocation concentration for a 20% decrease of FEy1
(PC20) was >20 mg/ml in all cases.
Injection of S-i â€˜-[â€˜8F]fluorocarazololby the remote-con
trolled pump did not cause any change in blood pressure, heart
rate or electrocardiogram of the volunteers. Transverse sections
of thethoraxof a singlesubjectbeforeandafteringestionof
pindolol are shown in Figure 1. The volunteer is on his back; the
direction ofobservation is from his feet towards his head. In the
control study (without pindolol), the heart and lungs were
clearly visible; at planes originating from the lower part of the
thorax the right liver lobe came into the field of view. After
ingestion of pindolol, heart and lungs were no longer visible,
but the hepatic uptake of S-i â€˜-[â€˜8F]fluorocarazololwas unaf
fected. Inhalation of salbutamol before administration of the
radioligand did not alter the PET images in any way. PET
images acquired after salbutamol treatment are therefore not
shown in Figure 1.
Kineticsof S-I'-[Fluonne-18]Ruorocarazolol Uptake in
Heart and Lung
After injection of the radioligand, tissue levels of radioactiv
ity rose to a maximum followed by a rapid decline to a
relatively stable plateau (Fig. 2). This â€˜slowkinetic phase'
represented a higher level of radioactivity per volume in the
heart than in the lungs (Fig. 2). A biexponential function was
fittedto the tissuewashoutcurves;parameterscalculatedforthe
slow component of this function (i.e., the slow kinetic phase)
are shown in Table 2. Salbutamol did not significantly influence
the slow kinetic phase in either heart or lungs, but pretreatment
of subjects with pindolol induced a more rapid washout of
radioactivity from the target organs (Fig. 2; Table 2). Pindolol
reduced cardiac and pulmonary radioactivity to 39% and 56%
of the control at 60 mm postinjection, whereas salbutamol had
no significant effect (average reduction <5% from 30â€”60mm
postinjection, Fig. 2).
Clearance of Radloactivftyfrom Plasma
Injected radioactivity was initially rapidly cleared from
plasma (to 6.3% Â±0.3% of the peak level within 10 mm), but
the subsequent clearance was slow (to 3.1% Â±0.4% after 60
min, see Fig. 3). Inhaled salbutamol did not affect the plasma
clearanceof the radioligand,but ingestedpindololretardedit.
Circulating levels of radioactivity from 10 to 60 mm postinjec
tion were significantly (1.7â€”1.8fold) higher in pindolol-treated
subjects than in control subjects (Fig. 3).
Appearance of Labeled Metabolites in Plasma
Radioactive metabolites appeared rapidly in human plasma
after injection ofS-l â€˜-[â€˜8F]fluorocarazolol.The fraction of total
plasmaradioactivityrepresentingunmodifiedliganddecreased
from >99.8% at t = 0 to ca. 20% after 60 mm (Fig. 4).
Salbutamol did not affect the ratio of [parent]/[metabolites] in
plasma, but pindolol increased it (Fig. 4). The fraction of total
plasma radioactivity representing parent compound was signif
icantly higher in pindolol-treated subjects than in control
subjects from 5 to 60 mm postinjection (Fig. 4).
7
0 10 20 30 40 50 60
Timepost injectionmm
FIGUREa ClearanceofradkactMtyfromhumanr@asmaafterinjectionf
S-i â€˜-[18Fjfluorocarazolol(data plottedas mean Â±s.d.).
ventricle of the heart was drawn using the emission scan and the
time frame 14â€”60mm postinjection of the unblocked study.
Time-activity curves for the ROIs were calculated using ECAT
software (version 6.5D) running on a SUN/SPARC workstation.
Since data from different studies had to be compared, values of
tissue uptake were normalized to an injected radioactivity of 74
MBq (2 mCi) and a body weight of 70 kg. The time-activity data
were exported to an IBM-compatible PC and characterized using a
nonlinear regression data analysis program (EnzFitter, Elsevier
Biosoft). Differences between groups were tested using one-way
analysis of variance and commercial software (Statistix, NH
Analytical Software). A two-tailed probability smaller than 0.05
was considered statistically significant.
FIGURE4. lime-courseofunchangedS-iâ€˜-r@Fjfluorocarazoblinhuman
plasma. The fraction of total plasma radioactivity representing unmodified
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2 FIGURE5. Thsue-to-piesma concentra
tion ratiosof 5-1â€˜-[18Fjfluorocarazololin
humantissues.TissueradloactMtywas
assumed to be 100% unmodifIedradio
ligand; @maradioactivity was co@
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first-pass metabolism in humans (Table 3). However, CGP
12177 did not appreciably cross the blood-brain barrier whereas
fluorocarazolol could be used for PET studies of beta-adreno
ceptors in the central nervous system (data reported elsewhere).
Receptor Occupancy in Target Tissues
Tissue concentrations of fluorocarazolol were calculated
from PET images using the calibration factor of the camera and
the specific activity ofthe injected radioligand. During the slow
kinetic phase, maximal concentrations ranged from 0.03 to
0.085 pmole/ml in the heart and from 0.015 to 0.06 pmole/ml in
the lungs (raw data; tissue volume including air).
Washout of â€˜8Ffrom the target tissues after injection of
s-iâ€˜-[â€˜8F]fluorocarazololshowedthetypicalbiexponentialk
netics that have also been described for S-[' â€˜C]CGP12177, an
established beta-adrenoceptor ligand (19). The rapid component
of this kinetics represented the vascular phase and nonspecific
binding, whereas the slow component mainly represented ra
dioligand binding to beta-adrenoceptors (19). Estimations of
beta-adrenoceptor density in the heart of healthy volunteers
using S-[' â€˜C]-CGP12177 ranged from 7.0 Â±1.4 [uncorrected
mean Â±s.d. (24)] to 10.0 Â± 1.7 pmole/ml [corrected for
spillover from blood and partial volume effect (25)]. Pulmonary
beta-adrenoceptor density in healthy subjects, measured by the
same technique, were 2.0 Â±0.2 pmole/ml tissue (including air)
(18). Maximal receptor occupancies in the present study,
calculated from tissue concentrations of S-i â€˜-[â€˜8F]fluorocara
zolol and in vivo data for tissue B,@ (18,24,25) ranged from
0.4 to 1.2% in the heart and from 0.75% to 3% in the lungs (see
Table 1). At the end of the experiment (50â€”60mm post
injection), values were ca 0.50% lower. It is therefore not
surprising that injection of S-i â€˜-[â€˜8Fjfluorocarazololhad no
measurable effect on heart rate or blood pressure, although
carazolol has no intrinsic sympathomimetic activity.
Mechanisms Underlying Tissue Uptake of Radioactivity
Orally administered pindolol had a strong effect on S-i'-
[â€˜8F}fluorocarazolol uptake in the heart and lung but not in the
liver of healthy volunteers (Figs. 1, 2, 5; Table 2). The pindolol
effect suggests that myocardial and pulmonary radioactivity
represents radioligand binding to beta-adrenoceptors, whereas
liver uptake is largely determined by other mechanisms (e.g.,
membrane transport and metabolism). Inhalation of salbutamol
had no measurable effect on pulmonary radioactivity at inter
vals >20 mm although salbutamol seemed to induce a more
Tissue-to-Plasma Concentration Ratios
If tissue radioactivity is considered to represent bound
radioligand only (see Discussion) and the contribution of
radioactive metabolites is subtracted from total plasma radio
activity, [tissue]/[plasmaj concentration ratios of the radioli
gand can be calculated. In heart and lung, these ratios slowly
rise to a plateau value that is reached after 45â€”50mm (Fig. 5).
DISCUSSION
Mvantages and D@advanthges of U@ngS-1'-[fluoiine-18-]
Fluorocarazolol Rather Than S-[Carbon-II]CGP 12177
We could produce S-['8F]fluorocarazolol with lower maxi
mum yield than S-[1 â€˜C]-CGP 12177 but with much higher
specific activity (Table 3). The yield could still be optimized
and it was already sufficient for human studies. The high
specific activity of S-['8F]fluorocarazolol allowed PET scan
ning to be performed with low receptor occupancy, i.e., lack of
pharmacological effects (see below). In contrast, planned stud
ies with S-[' â€˜C]CGP 12177 often had to be canceled for
medical-ethical reasons as no low-mass injection was possible.
Both CGP-12l77 and fluorocarazolol are potent, nonsubtype
selective beta-adrenoceptor antagonists with subnanomolar af
finities to beta-adrenoceptors (Table 3). CGP 12177 is hydro
philic whereas fluorocarazolol is a more lipophilic ligand. The
lipophilicity of fluorocarazolol as compared to CGP-12 177
resulted in a higher nonspecific binding and a more extensive
TABLE3
Properties of the Beta-Adrenoceptor Ugands
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rapid washout of nonspecifically bound radioligand probably
due to an increase of pulmonary blood flow (Fig. 2; Table 2).
The administered amount of salbutamol (2 X 200 p@g= 1670
nmole) was sufficient to occupy a substantial fraction of
receptors, even if only 10% of the dose would enter the lungs
[total amount ofpulmonary beta-2-adrenoceptors in humans ca.
10 nmole (18); affinity of salbutamol to these receptors l08 M
(26)]. Inhaled salbutamol occupies beta-adrenoceptors on
smooth muscle of the airways but the /32-agonistdoes not reach
the level of the alveoli. The fact that salbutamol did not affect
specific binding of S-i â€˜-[18F]fluorocarazolol in the lung there
fore suggests that the radioligand was mainly bound to alveolar
beta-adrenoceptors, which constitute >90% of the total beta
adrenoceptor pool in human lung (27).
Effect of Plndolol on RadIOI@andClearance
In the presence of pindolol, levels of radioactivity in plasma
from 10 to 60 min after injection of S-l â€˜-[â€˜8F]fluorocarazolol
were almost twice as high as in the control situation (Fig. 3).
Moreover, the ratio of the concentrations of parent/metabolites
was significantly increased (Fig. 4). The effect ofpindolol may
be caused by two different (but not mutually exclusive) mech
anisms:
1. Pindolol blocked beta-adrenoceptors and it caused a more
rapid washout of the radioligand from the target organs,
resulting in higher concentrations in plasma (see Fig. 2).
2. Pindolol competed with S-i â€˜-[â€˜8F]fluorocarazololfor the
same metabolic pathway in the liver and thus caused less
rapid degradation and excretion of the radioligand.
The former mechanism seemed more likely, as the clearance
of a slowly metabolized radiopharmaceutical, S-i â€˜-[â€˜â€˜C]CGP
12177, was similarly affected by prior administration of pro
pranolol (16).
CONCLUSION
S-i â€˜-[â€˜8F]fluorocarazololseemed a useful radiopharmaceuti
cal for PET studies of beta-adrenoceptors in human heart and
lungs. The myocardium and the peripheral lung were clearly
visualized; uptake in these tissues was strongly inhibited after
ingestion of pindolol. Tissue-to-plasma concentration ratios of
the radioligand increased to a plateau value which was reached
at 45â€”50mm postinjection. Kinetics of â€˜8Fuptake and release
in the target organs were compatible with determination of
receptor densities with compartment models. After submission
of this article, another article was published in which it was
shown that myocardial beta-adrenoceptor density in experimen
tal animals can be accurately determined by a dual-injection
protocol (28).
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